Wells Fargo Maintains Equal-Weight on Kezar Life Sciences, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has maintained an Equal-Weight rating on Kezar Life Sciences (NASDAQ:KZR) but has reduced the price target from $4 to $2.
November 14, 2023 | 1:29 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wells Fargo analyst Derek Archila maintains an Equal-Weight rating on Kezar Life Sciences but lowers the price target from $4 to $2.
The reduction in price target by Wells Fargo is likely to be viewed negatively by investors, as it suggests a lower expected future stock price for Kezar Life Sciences. This could lead to a short-term decline in KZR's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100